Newswise — PHILADELPHIA—The “scarred villain” is one of the oldest tropes in film and literature, from Scar in “The Lion King” to Star Wars’ Darth Vader and the Joker in “The Dark Knight.” The trope is likely rooted in a long-evolved human bias against facial anomalies — atypical features such as growths, swelling, facial paralysis, and scars. A new brain-and-behavior study from researchers in the Perelman School of Medicine at the University of Pennsylvania illuminates this bias on multiple levels.
The researchers, whose findings were published this week in the Annals of the New York Academy of Sciences, used surveys, social simulations, and functional MRI (fMRI) studies to study hundreds of participants’ responses and attitudes towards attractive, average, and anomalous faces. The findings clarify how the “anomalous-is-bad” stereotype manifests, and implicate a brain region called the amygdala as one of the likely mediators of this stereotype.
“Understanding the psychology of the ‘anomalous-is-bad’ stereotype can help, for example, in the design of interventions to educate the public about the social burdens shouldered by people who look different,” said lead author Clifford Workman, PhD, a postdoctoral researcher in the Penn Center for Neuroaesthetics. The center is led by Anjan Chatterjee, MD, a professor of Neurology at Penn Medicine, who was senior author of the study.
Bias against people with facial disfigurements has been demonstrated in various prior studies. Researchers broadly assume that this bias reflects ancient adaptive traits which evolved to promote healthy mate selection, for example, and to steer us clear of people who have potentially communicable diseases. Regardless the cause, for many people, their facial anomalies render them unjust targets of discrimination.
In their study, Workman and colleagues investigated how this bias manifests at different levels, from expressed attitudes towards faces, to actual behavior during simulated social interactions, and even down to brain responses when viewing faces.
In one part of the study, the researchers showed a set of faces that were either average-looking, attractive, or anomalous to 403 participants from an online panel, and asked them to rate the depicted people on various measures. The researchers found that, compared to more attractive faces, participants considered anomalous faces less trustworthy, less content, and more anxious, on average. The anomalous faces also made the participants feel less happy. Participants also acknowledged harboring “explicit bias” reflected in negative expectations about people with anomalous faces as a group.
In the other part of the study, Workman and colleagues examined moral attitudes and dispositions, the behavior during simulated social interaction, and fMRI-measured brain responses, for 27 participants who viewed similar sets of faces.
Here again there was some evidence of the anomalous-is-bad habit of thinking, though it was not clear that this translated into mistreatment of people with anomalous faces. For example, in a simulated donation game measuring pro-sociality — the willingness to be positive and helpful towards another — the participants were not significantly less pro-social towards anomalous-looking people. However, participants in the highest tier of socioeconomic status, compared to the others, were significantly less pro-social towards anomalous-looking people.
On fMRI scans, brain regions called the amygdala and the fusiform gyri showed significant neural responses specifically to anomalous faces. Activity in a portion of the left amygdala, which correlated with less pro-sociality towards anomalous faces, also seemed related to participants’ beliefs about justice in the world and their degree of empathic concern.
“We hypothesize that the left amygdala integrates face perception with moral emotions and social values to guide behavior, such that weaker emotional empathy, and a stronger belief that the world is just, both facilitate dehumanizing people with facial anomalies,” Chatterjee said.
Analyzing such responses is inherently challenging, because they involve a mix of subjective perceptions, such as the “visual salience,” or relative importance, of a face, and the “emotional arousal” elicited by seeing the face. To inform future research, as part of the study, the team used the fMRI data to clarify which brain regions are associated with these distinct aspects of the experience of seeing faces.
Additional co-authors included Stacey Humphries, Franziska Hartung, Geoffrey Aguirre, and Joseph Kable.
The research was supported by the Penn Center for Human Appearance and the National Institute of Dental & Craniofacial Research of the National Institutes of Health (F32DE029407).
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.6 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $494 million awarded in the 2019 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 43,900 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2019, Penn Medicine provided more than $583 million to benefit our community.
MEDIA CONTACTRegister for reporter access to contact details
F32DE029407; Annals of the New York Academy of Sciences, Feb-2021